Published in Crit Rev Oncol Hematol on August 03, 2008
Fast and sensitive pretargeted labeling of cancer cells through a tetrazine/trans-cyclooctene cycloaddition. Angew Chem Int Ed Engl (2009) 3.63
Biomedical applications of tetrazine cycloadditions. Acc Chem Res (2011) 2.10
Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections. PLoS Pathog (2012) 1.36
Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells. J Clin Invest (2013) 1.04
Fluorescent affibody peptide penetration in glioma margin is superior to full antibody. PLoS One (2013) 0.94
EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem (2012) 0.90
Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. Mol Immunol (2012) 0.89
Status of targeted therapies in the adjuvant treatment of colon cancer. J Gastrointest Oncol (2013) 0.89
Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro. Oncogene (2013) 0.89
Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells. Br J Cancer (2009) 0.83
miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells. Oncotarget (2016) 0.79
Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy. Mol Ther Oncolytics (2015) 0.79
Efficient blockade of Akt signaling is a determinant factor to overcome resistance to matuzumab. Mol Cancer (2011) 0.78
Targeted therapy: resistance and re-sensitization. Chin J Cancer (2015) 0.76
A wortmannin-cetuximab as a double drug. Bioconjug Chem (2009) 0.75
Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment. Front Pharmacol (2016) 0.75
Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab. Oncotarget (2016) 0.75
A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition. Cancer Cell Int (2016) 0.75
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med (2014) 4.81
Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol (2013) 3.67
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol (2009) 3.48
Aprepitant for erlotinib-induced pruritus. N Engl J Med (2010) 2.97
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res (2012) 2.95
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol (2008) 2.40
Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell (2010) 2.38
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist (2008) 2.22
Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res (2007) 2.18
Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab (2014) 2.17
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol (2007) 2.08
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol (2008) 1.99
Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol (2012) 1.75
Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res (2002) 1.66
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res (2003) 1.61
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer (2010) 1.56
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev (2010) 1.45
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One (2011) 1.44
Role of GPR30 in testicular germ cell tumors: a potential new anticancer target. Cancer Biol Ther (2011) 1.43
MUC2 but not MUC5 expression correlates with prognosis in radically resected pancreatic cancer patients. Cancer Biol Ther (2009) 1.42
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist (2010) 1.35
Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res (2003) 1.34
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol (2011) 1.27
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer (2008) 1.27
Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer (2006) 1.25
Distribution of the serine protease HtrA1 in normal human tissues. J Histochem Cytochem (2003) 1.21
Longterm results after resection of simultaneous and sequential lung and liver metastases from colorectal carcinoma. J Am Coll Surg (2003) 1.19
In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother (2008) 1.16
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res (2005) 1.16
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev (2010) 1.15
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol (2006) 1.14
Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. J Exp Clin Cancer Res (2013) 1.12
Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: doubts no more. Expert Opin Biol Ther (2008) 1.12
Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk Italian population. Int J Cancer (2006) 1.11
Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res (2013) 1.09
Status of adjuvant endocrine therapy for breast cancer. Breast Cancer Res (2014) 1.07
Comment and reply on: pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens. Expert Opin Ther Targets (2013) 1.07
Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res (2010) 1.06
SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors. Mod Pathol (2012) 1.05
Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer. J Cell Physiol (2010) 1.02
Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress. Clin Cancer Res (2005) 1.02
Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nat Clin Pract Oncol (2007) 1.02
R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. J Cell Physiol (2007) 1.02
Reelin expression in human prostate cancer: a marker of tumor aggressiveness based on correlation with grade. Mod Pathol (2007) 1.02
Target therapies in pancreatic carcinoma. Curr Med Chem (2014) 1.01
Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. Int J Cancer (2013) 1.01
Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy". Breast Cancer Res Treat (2014) 1.00
Cerebellar metastasis from pancreatic adenocarcinoma. A case report. Pancreatology (2006) 1.00
Role of Apaf-1, a key regulator of apoptosis, in melanoma progression and chemoresistance. Exp Dermatol (2005) 0.99
Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. Sci Rep (2015) 0.99
Hypoxia inducible factor-1 expression mediates myocardial response to ischemia late after acute myocardial infarction. Int J Cardiol (2005) 0.97
Infarct-related artery occlusion, tissue markers of ischaemia, and increased apoptosis in the peri-infarct viable myocardium. Eur Heart J (2005) 0.97
Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report. Support Care Cancer (2007) 0.97
Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat Clin Pract Oncol (2006) 0.97
Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer. Clin Chem Lab Med (2007) 0.96
Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. Int J Cancer (2009) 0.96
Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. PLoS One (2013) 0.95
Identification of genes down-regulated during melanoma progression: a cDNA array study. Exp Dermatol (2003) 0.95
Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC). Curr Cancer Drug Targets (2011) 0.94
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer (2011) 0.94
Ovarian cancer standard of care: are there real alternatives? Chin J Cancer (2015) 0.94
Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. Clin Cancer Res (2008) 0.93
High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. Oncologist (2012) 0.93